In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin

Journal of Controlled Release

Volumn 146, Issue 1, 2010, Pages 37-44

  Milewski, Mikolaj ^a   Yerramreddy, Thirupathi Reddy ^a   Ghosh, Priyanka ^a   Crooks, Peter A ^a   Stinchcomb, Audra L ^a  

^a University of Kentucky   (United States)

Author keywords

Microneedles; Naltrexone; PEGylation; Prodrug; Transdermal drug delivery

Indexed keywords

MICRONEEDLES; NALTREXONE; PEGYLATION; PRODRUGS; TRANSDERMAL DRUG DELIVERY;

BIOCHEMISTRY; CONCENTRATION (PROCESS); CONTROLLED DRUG DELIVERY; NEEDLES; VISCOSITY;

DRUG PRODUCTS;

MACROGOL; NALTREXONE; POLYETHYLENEGLYCOL NALTREXONE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; IN VITRO STUDY; MICRONEEDLE; MINIPIG; NEEDLE; NONHUMAN; PRIORITY JOURNAL; SKIN; SKIN PERMEABILITY; VISCOSITY; WATER LOSS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; MODELS, BIOLOGICAL; NALTREXONE; NEEDLES; PERMEABILITY; POLYETHYLENE GLYCOLS; PRODRUGS; SKIN; SKIN ABSORPTION; SOLUBILITY; SWINE; SWINE, MINIATURE; TISSUE DISTRIBUTION; VISCOSITY;

EID: 77955307328     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.05.034     Document Type: Article

References (47)

1. F.K. Elias PM, Fluhr J.W., in: E. A. Freedberg IM, Wolff K, Austen KF, Goldsmith LA, Katz SI (Ed.), Mc-Graw Hill, New York, 2003.
2. Madison K.C. Barrier function of the skin: "La raison d'etre" of the epidermis. Journal Invest Dermatology 2003, 121(2):231-241.
3. Harding Clive R. The stratum corneum: structure and function in health and disease. Dermatologic Therapy 2004, 17(Suppl 1):6-15.
4. Michaels A.S., Chandrasekaran S.K., Shaw J.E. Drug permeation through human skin theory and in vitro experimental measurement. AIChE Journal 1975, 21(5):985-996.
5. Tojo K. Random brick model for drug transport across stratum corneum. Journal of Pharmaceutical Sciences 1987, 76(12):889-891.
6. Prausnitz M.R., Mitragotri S., Langer R. Current status and future potential of transdermal drug delivery. Nature Reviews Drug Discovery 2004, 3(2):115-124.
7. Arora A., Prausnitz M.R., Mitragotri S. Micro-scale devices for transdermal drug delivery. International Journal of Pharmaceutics 2008, 364(2):227-236.
8. Prausnitz M.R., Langer R. Transdermal drug delivery. Nature Biotechnology 2008, 26(11):1261-1268.
9. Henry S., McAllister D.V., Allen M.G., Prausnitz M.R. Microfabricated microneedles: a novel approach to transdermal drug delivery. Journal of Pharmaceutical Sciences 1998, 87(8):922-925.
10. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., O'Brien C.P. Naltrexone and alcohol dependence. Role of subject compliance. Archives of General Psychiatry 1997, 54(8):737-742.
11. Paudel K.S., Nalluri B.N., Hammell D.C., Valiveti S., Kiptoo P., Hamad M.O., Crooks P.A., Stinchcomb A.L. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo. Journal of Pharmaceutical Sciences 2005, 94(9):1965-1975.
12. Valiveti S., Paudel K.S., Hammell D.C., Hamad M.O., Chen J., Crooks P.A., Stinchcomb A.L. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs. Pharmaceutical Research 2005, 22(6):981-989.
13. Banks S.L., Pinninti R.R., Gill H.S., Crooks P.A., Prausnitz M.R., Stinchcomb A.L. Flux across microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro. Pharmaceutical Research 2008, 25(7):1677-1685.
14. Banks S.L., Paudel K.S., Pinninti R.R., Gill H.S., Crooks P.A., Brogden N.K., Prausnitz M.R., Stinchcomb A.L. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. Journal of Pharmaceutical Sciences 2010, 99(7):3072-3080.
15. Wermeling D.P., Banks S.L., Hudson D.A., Gill H.S., Gupta J., Prausnitz M.R., Stichcomb A.L. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(6):2058-2063.
16. Bruckdorfer T. PEGylation - a key technology to improve solubility and pharmacokinetic of peptides, proteins and other biopharmaceuticals for superior drug delivery. Biopolymers 2009, 92(4):337-337.
17. Riley T., Riggs-Sauthier J. The benefits and challenges of PEGylating small molecules. Pharmaceutical Technology 2008, 32(7). 88, 90-92, 94.
18. Basu A., Yang K., Wang M.L., Liu S., Chintala R., Palm T., Zhao H., Peng P., Wu D.C., Zhang Z.F., Hua J., Hsieh M.C., Zhou J., Petti G., Li X.G., Janjua A., Mendez M., Liu J., Longley C., Zhang Z., Mehlig M., Borowski V., Viswanathan M., Filpula D. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjugate Chemistry 2006, 17(3):618-630.
19. Harris J.M., Chess R.B. Effect of PEGylation on pharmaceuticals. Nature Reviews Drug Discovery 2003, 2(3):214-221.
20. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today 2005, 10(21):1451-1458.
21. Bonina F.P., Puglia C., Barbuzzi T., de Caprariis P., Palagiano F., Rimoli M.G., Saija A. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. European Journal of Pharmaceutical Sciences 2001, 14(2):123-134.
22. Thomas J.D., Majumdar S., Sloan K.B. Soft alkyl ether prodrugs of a model phenolic drug: the effect of incorporation of ethyleneoxy groups on transdermal delivery. Molecules 2009, 14(10):4231-4245.
23. N'Da D.D., Breytenbach J.C. Synthesis of methoxypoly(ethylene glycol) carbonate prodrugs of zidovudine and penetration through human skin in vitro. Journal of Pharmacy and Pharmacology 2009, 61(6):721-731.
24. Yerramreddy T.R., Milewski M., Penthala N.R., Stinchcomb A.L., Crooks P.A. Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery. Bioorganic and Medicinal Chemistry Letters 2010, 20(11):3280-3283.
25. Wester R.C., Christoffel J., Hartway T., Poblete N., Maibach H.I., Forsell J. Human cadaver skin viability for in vitro percutaneous absorption: Storage and detrimental effects of heat-separation and freezing. Pharmaceutical Research 1998, 15(1):82-84.
26. Messager S., Hann A.C., Goddard P.A., Dettmar P.W., Maillard J.Y. Assessment of skin viability: is it necessary to use different methodologies?. Skin Research Technology. 2003, 9(4):321-330.
27. Shaikh N.A., Ademola J.I., Maibach H.I. Effects of freezing and azide treatment of in vitro human skin on the flux and metabolism of 8-methoxypsoralen. Skin Pharmacology 1996, 9(4):274-280.
28. Ahlstrom L.A., Cross S.E., Mills P.C. The effects of freezing skin on transdermal drug penetration kinetics. Journal of Veterinary Pharmacology & Therapeutics 2007, 30(5):456-463.
29. Babu R.J., Kanikkannan N., Kikwai L., Ortega C., Andega S., Ball K., Yim S., Singh M. The influence of various methods of cold storage of skin on the permeation of melatonin and nimesulide. Journal of Controlled Release 2003, 86(1):49-57.
30. Moody R.P., Yip A., Chu I. Effect of cold storage on in vitro human skin absorption of six 14C-radiolabeled environmental contaminants: benzo[a]pyrene, ethylene glycol, methyl parathion, naphthalene, nonyl phenol, and toluene. Journal Toxicology Environment Health Part A 2009, 72(8):505-517.
31. Gill H.S., Prausnitz M.R. Coated microneedles for transdermal delivery. Journal of Controlled Release 2007, 117(2):227-237.
32. Chilcott R.P., Stubbs B., Ashley Z. Habituating pigs for in-pen, non-invasive biophysical skin analysis. Laboratory animals 2001, 35(3):230-235.
33. Gendimenico G.J., Liebel F.T., Fernandez J.A., Mezick J.A. Evaluation of topical retinoids for cutaneous pharmacological activity in Yucatan microswine. Archives of Dermatological Research 1995, 287(7):675-679.
34. Kanikkannan N., Burton S., Patel R., Jackson T., Sudhan Shaik M., Singh M. Percutaneous permeation and skin irritation of JP-8+100 jet fuel in a porcine model. Toxicology Letters 2001, 119(2):133-142.
35. Hussain M.A., Koval C.A., Myers M.J., Shami E.G., Shefter E. Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach. Journal of Pharmaceutical Sciences 1987, 76(5):356-358.
36. Yosipovitch G., Xiong G.L., Haus E., Sackett-Lundeen L., Ashkenazi I., Maibach H.I. Time-dependent variations of the skin barrier function in humans: transepidermal water loss, stratum corneum hydration, skin surface pH, and skin temperature. Journal of Invest Dermatology 1998, 110(1):20-23.
37. Firooz A., Gorouhi F., Davari P., Atarod M., Hekmat S., Rashighi-Firoozabadi M., Solhpour A. Comparison of hydration, sebum and pH values in clinically normal skin of patients with atopic dermatitis and healthy controls. Clinical and experimental dermatology 2007, 32(3):321-322.
38. Buraczewska I. Outside and inside skin pH. Dry Skin and Moisturizers 2006, 161-169. 2nd Edition.
39. Ohman H., Vahlquist A. The pH gradient over the stratum corneum differs in X-linked recessive and autosomal dominant ichthyosis: a clue to the molecular origin of the "acid skin mantle"?. Journal Invest Dermatology 1998, 111(4):674-677.
40. Fujii M., Yamanouchi S., Hori N., Iwanaga N., Kawaguchi N., Matsumoto M. Evaluation of yucatan micropig skin for use as an in vitro model for skin permeation study. Biological & Pharmaceutical Bulletin 1997, 20(3):249-254.
41. Eggleston T.A., Roach W.P., Mitchell M.A., Smith K., Oler D., Johnson T.E. Comparison of two porcine (Sus scrofa domestica) skin models for in vivo near-infrared laser exposure. Comparative Medicine 2000, 50(4):391-397.
42. Gore A.V., Liang A.C., Chien Y.W. Comparative biomembrane permeation of tacrine using Yucatan minipigs and domestic pigs as the animal model. Journal of Pharmaceutical Sciences 1998, 87(4):441-447.
43. Kretsos K., Miller M.A., Zamora-Estrada G., Kasting G.B. Partitioning, diffusivity and clearance of skin permeants in mammalian dermis. International Journal of Pharmaceutics 2008, 346(1-2):64-79.
44. M. Milewski, A.L. Stinchcomb, Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Pharm Res in press (2010).
45. Flynn G.L., Yalkowsky S.H., Roseman T.J. Mass transport phenomena and models. Theoretical concepts. Journal of Pharmaceutical Sciences 1974, 63(4):479-510.
46. Chirife J., Buera M.P. A simple model for predicting the viscosity of sugar and oligosaccharide solutions. Journal of Food Engineering 1997, 33:221-226.
47. M. Milewski, N.K. Brogden, A.L. Stinchcomb, Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opinion on Drug Delivery 7 (5) (2010) 617-629.